Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Matthias Büttner - , Johannes Gutenberg-Universität Mainz (Autor:in)
  • Susanne Singer - , Johannes Gutenberg-Universität Mainz (Autor:in)
  • Leopold Hentschel - , Universitäts KrebsCentrum Dresden, Nationales Zentrum für Tumorerkrankungen (NCT) Dresden (Autor:in)
  • Stephan Richter - , Medizinische Klinik und Poliklinik I, Medizinische Klinik und Poliklinik I, Technische Universität Dresden (Autor:in)
  • Peter Hohenberger - , Universität Heidelberg (Autor:in)
  • Bernd Kasper - , Universität Heidelberg (Autor:in)
  • Dimosthenis Andreou - , Westfälische Wilhelms-Universität Münster, Helios Kliniken Gruppe (Autor:in)
  • Daniel Pink - , Helios Kliniken Gruppe, Ernst-Moritz-Arndt-Universität Greifswald (Autor:in)
  • Kathy Taylor - , Johannes Gutenberg-Universität Mainz (Autor:in)
  • Karin Arndt - , German Sarcoma Foundation (Autor:in)
  • Martin Bornhäuser - , Medizinische Klinik und Poliklinik I, Universitäts KrebsCentrum Dresden, Nationales Zentrum für Tumorerkrankungen (NCT) Dresden, Medizinische Klinik und Poliklinik I, Technische Universität Dresden (Autor:in)
  • Jochen Schmitt - , Zentrum für evidenzbasierte Gesundheitsversorgung, Universitätsmedizin Mannheim, Universität Heidelberg, Technische Universität Dresden (Autor:in)
  • Markus K. Schuler - , Technische Universität Dresden (Autor:in)
  • Martin Eichler - , Universitäts KrebsCentrum Dresden, Nationales Zentrum für Tumorerkrankungen (NCT) Dresden, Medizinische Klinik und Poliklinik I, Technische Universität Dresden (Autor:in)

Abstract

Purpose: Cancer patients have been shown to frequently suffer from financial burden before, during, and after treatment. However, the financial toxicity of patients with sarcoma has seldom been assessed. Therefore, the aim of this study was to evaluate whether financial toxicity is a problem for sarcoma patients in Germany and identify associated risk factors. Methods: Patients for this analysis were obtained from a multicenter prospective cohort study conducted in Germany. Using the financial difficulties scale of the EORTC QLQ-C30, financial toxicity was considered to be present if the score exceeded a pre-defined threshold for clinical importance. Comparisons to an age- and sex-matched norm population were performed. A multivariate logistic regression using stepwise backward selection was used to identify factors associated with financial toxicity. Results: We included 1103 sarcoma patients treated in 39 centers and clinics; 498 (44.7%) patients reported financial toxicity. Sarcoma patients had 2.5 times the odds of reporting financial difficulties compared to an age- and sex-matched norm population. Patient age < 40 and > 52.5 years, higher education status, higher income, and disease progression (compared to patients with complete remission) were associated with lower odds of reporting financial toxicity. Receiving a disability pension, being currently on sick leave, and having a disability pass were statistically significantly associated with higher odds of reporting financial toxicity. Conclusion: Financial toxicity is present in about half of German sarcoma patients, making it a relevant quality of life topic for patients and decision-makers.

Details

OriginalspracheEnglisch
Seiten (von - bis)187-196
Seitenumfang10
FachzeitschriftSupportive care in cancer
Jahrgang30
Ausgabenummer1
PublikationsstatusVeröffentlicht - 11 Juli 2021
Peer-Review-StatusJa

Externe IDs

PubMed 34247310
ORCID /0000-0001-9654-2207/work/142254159

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Burden, Cancer, Financial difficulties, Financial toxicity, Germany, Sarcoma

Bibliotheksschlagworte